ABVX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Abivax SA has a consensus price target of $152.70, signalling upside risk potential of 33.97%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 66.7%. Given that DBV Technologies SA has higher upside potential than Abivax SA, analysts believe DBV Technologies SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Abivax SA's net income of -$179.2M is lower than DBV Technologies SA's net income of -$33M. Notably, Abivax SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Abivax SA has a consensus price target of $152.70, signalling upside risk potential of 33.97%. On the other hand Innate Pharma SA has an analysts' consensus of $5.75 which suggests that it could grow by 223.03%. Given that Innate Pharma SA has higher upside potential than Abivax SA, analysts believe Innate Pharma SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.755%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Innate Pharma SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Innate Pharma SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 22.99x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Inventiva SA's return on equity of --.

Abivax SA has a consensus price target of $152.70, signalling upside risk potential of 33.97%. On the other hand Inventiva SA has an analysts' consensus of $15.26 which suggests that it could grow by 123.35%. Given that Inventiva SA has higher upside potential than Abivax SA, analysts believe Inventiva SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.184%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Inventiva SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Inventiva SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 39.76x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Abivax SA's net margin of 31.72%. Abivax SA's return on equity of -- beat Eli Lilly & Co.'s return on equity of 106.26%.

Abivax SA has a consensus price target of $152.70, signalling upside risk potential of 33.97%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Abivax SA has higher upside potential than Eli Lilly & Co., analysts believe Abivax SA is more attractive than Eli Lilly & Co..

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Abivax SA pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abivax SA quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Abivax SA's net income of -$179.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Abivax SA's price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.